Pandion Therapeutics sought $58 million Series A funding to advance drug programs for autoimmune and inflammatory diseases

Pandion Therapeutics declared the completion of a $58 million Series A financing that will be utilized to further its drug programs for autoimmune and inflammatory diseases in addition to persistent enhancement of the company’s technology platform and pipeline.

Alan Crane, Entrepreneur Partner at Polaris Partners and Chairman of the Board of Pandion Therapeutics said “Pandion is positioned to shift the paradigm for treating inflammatory and autoimmune diseases as well as transplant recipients by developing therapeutic antibodies that act at the local site of disease, offering the potential for significantly improved therapeutic options beyond systemic immunosuppressive treatments.”

Pandion has developed its own therapeutic platform based on biospecific antibodies with targeting fragments that bind to specific tissues at the local site of inflammatory disease, coupled with effector molecules that modulate immune activity in order to restore immune homeostasis. Pandion’s initial areas of drug development include inflammatory bowel disease, autoimmune liver disease, kidney diseases, type 1 diabetes, and autoimmune skin conditions followed by multiple patents covering its technology platform and applications. The unique localized immunomodulation of Pandion’s bi-specific antibodies is designed to provide a durable, tissue-specific effect at the site of disease, while avoiding the systemic immunosuppression of current treatments for autoimmune diseases and transplantation. Pandion vows to remain committed to advancements in the field of immune system regulation,  including immuno-oncology discoveries about pathways by which tumors avoid immune recognition and induce long-term immune tolerance